论文部分内容阅读
目的观察沙美特罗/丙酸氟替卡松(舒利迭)治疗慢性阻塞性肺疾病的疗效。方法 2005年6月-2008年10月慢性阻塞性肺疾病患者160例,随机分成治疗组和对照组各80例,两组均给予慢性阻塞性肺疾病常规抗感染、祛痰和解痉治疗,治疗组在此基础上给予沙美特罗/丙酸氟替卡松。结果治疗组治疗前后临床症状积分和肺功能有统计学意义(P<0.05),且未发现有任何毒副作用,对照组治疗前后无统计学意义(P>0.05)。治疗后治疗组临床症状积分和肺功能明显优于对照组(P<0.05)。结论沙美特罗/丙酸氟替卡松能明显改善慢性阻塞性肺疾病患者的临床症状和肺功能。
Objective To observe the effect of salmeterol / fluticasone propionate on patients with chronic obstructive pulmonary disease. Methods From June 2005 to October 2008, 160 patients with COPD were randomly divided into treatment group (n = 80) and control group (n = 80). Both groups were given routine anti-infective, expectorant and antispasmodic treatment for chronic obstructive pulmonary disease On this basis, the group was given salmeterol / fluticasone propionate. Results Before and after treatment, the clinical symptom scores and lung function of the treatment group were statistically significant (P <0.05), and no toxic or side effects were found. There was no significant difference in the control group before and after treatment (P> 0.05). After treatment, the scores of clinical symptoms and lung function in the treatment group were significantly better than those in the control group (P <0.05). Conclusion Salmeterol / fluticasone propionate can significantly improve clinical symptoms and lung function in patients with chronic obstructive pulmonary disease.